Trials / Recruiting
RecruitingNCT06498986
A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase II clinical study is a study to explore the efficacy and safety of BL-B01D1 in combination with Osimertinib Mesylate Tablets in patients with histologically and/or cytologically confirmed locally advanced or metastatic non-small cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BL-B01D1 | Administration by intravenous infusion for a cycle of 3 weeks. |
| DRUG | Osimertinib Mesylate Tablets | Oral administration, 80mg daily for a cycle of 3 weeks. |
Timeline
- Start date
- 2024-07-31
- Primary completion
- 2026-08-01
- Completion
- 2026-08-01
- First posted
- 2024-07-12
- Last updated
- 2025-05-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06498986. Inclusion in this directory is not an endorsement.